Literature DB >> 7598496

Structural basis of selective cytochrome P450 inhibition.

J R Halpert1.   

Abstract

Isoform-selective cytochrome P450 inhibitors have greatly facilitated the characterization of the catalytic specificities and pharmacological and toxicological significance of individual P450 enzymes in experimental animals and humans. Recent advances in elucidating the enzymatic determinants of P450 substrate specificity now make it possible to explore how complementary properties of inhibitors and their target enzymes dictate inhibitor selectivity. A thorough understanding of the basis of specificity should lead to the rational design of a new generation of structure-based cytochrome P450 inhibitors for use as probes and modulators of P450 function in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598496     DOI: 10.1146/annurev.pa.35.040195.000333

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  16 in total

1.  An in vivo assay for elucidating the importance of cytochromes P450 for the ability of a wild mammalian herbivore (Neotoma lepida) to consume toxic plants.

Authors:  Michele M Skopec; Jael R Malenke; James R Halpert; M Denise Dearing
Journal:  Physiol Biochem Zool       Date:  2013-08-14       Impact factor: 2.247

2.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 3.  Potential of pharmacokinetic profiling for detecting herbal interactions with drugs.

Authors:  Veronika Butterweck; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

5.  Clotrimazole inhibits the recombinant human cardiac L-type Ca2+ channel alpha 1C subunit.

Authors:  I M Fearon; S G Ball; C Peers
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

6.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

Authors:  V A Eagling; J F Tjia; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 7.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Arginine to lysine 108 substitution in recombinant CYP1A2 abolishes methoxyresorufin metabolism in lymphoblastoid cells.

Authors:  Nicholas E Hadjokas; Renke Dai; Fred K Friedman; Michael J Spence; Barry J Cusack; Robert E Vestal; Yongsheng Ma
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 9.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

10.  Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.

Authors:  Helena Brandin; Olle Myrberg; Torgny Rundlöf; Ann-Kristin Arvidsson; Gunilla Brenning
Journal:  Eur J Clin Pharmacol       Date:  2007-03-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.